These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 8455394

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Severe hyperlipoproteinemia in congenital nephrotic syndrome of the Finnish type: effect of dialysis and kidney transplantation.
    Salo MK, Jaakkola O, Solakivi T, Ylä-Herttuala S.
    Acta Paediatr; 1993 Sep; 82(9):768-72. PubMed ID: 8241675
    [Abstract] [Full Text] [Related]

  • 8. Pathogenesis of hyperlipidemia in the nephrotic syndrome.
    Attman PO, Alaupovic P.
    Am J Nephrol; 1990 Sep; 10 Suppl 1():69-75. PubMed ID: 2256478
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P, Reiner Z, Brunetta B.
    Lijec Vjesn; 2002 Sep; 124(11-12):372-7. PubMed ID: 12679979
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A young Chinese man with nephrotic syndrome due to lipoprotein glomerulopathy.
    Lui DTW, Lee ACH, Yap DYH, Chan GSW, Tan KCB.
    J Clin Lipidol; 2019 Sep; 13(2):251-253. PubMed ID: 30685233
    [Abstract] [Full Text] [Related]

  • 13. Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine.
    Shafrir E.
    Isr J Med Sci; 1996 Jun; 32(6):390-7. PubMed ID: 8682644
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms and treatment of dyslipidemia of renal diseases.
    Toto RD, Vega GL, Grundy SM.
    Curr Opin Nephrol Hypertens; 1993 Sep; 2(5):784-90. PubMed ID: 7922219
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Dyslipoproteinemia in kidney diseases].
    Wróblewska M, Król E.
    Pol Tyg Lek; 1993 Sep; 48(20-22):494-7. PubMed ID: 8170821
    [No Abstract] [Full Text] [Related]

  • 17. Plasma lipid alterations in patients with chronic renal disease.
    Cramp DG.
    Crit Rev Clin Lab Sci; 1982 Sep; 17(1):77-101. PubMed ID: 6749432
    [Abstract] [Full Text] [Related]

  • 18. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?
    Keane WF, St Peter JV, Kasiske BL.
    Kidney Int Suppl; 1992 Oct; 38():S134-41. PubMed ID: 1405364
    [Abstract] [Full Text] [Related]

  • 19. Dietary cholesterol induced changes in lipid profile in patients with nephrotic syndrome and chronic renal failure.
    Jain PK, Arora RC, Agarwal N, Garg RK, Arora S, Gurbaxani RK, Sharma D.
    J Assoc Physicians India; 1991 Oct; 39(10):751-3. PubMed ID: 1816199
    [Abstract] [Full Text] [Related]

  • 20. Type II hyperlipoproteinemia, hyperapobetalipoproteinemia, and hyperalphalipoproteinemia following renal transplantation: prevalence and precipitating factors.
    Lowry RP, Soltys G, Mangel R, Kwiterovitch P, Sniderman AD.
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2229-32. PubMed ID: 3547921
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.